Core Insights - FMC Corporation experienced a significant decline in stock value after missing Q3 2025 revenue estimates and slashing its dividend by 86% to 8 cents, although it still offers a dividend yield of over 2.2% at current prices [1] Company Performance - The Q3 report is part of a broader trend, with FMC stock trading at its lowest levels since 2008, having lost a third of its market capitalization after missing Q4 2024 earnings estimates and being removed from the S&P 500 Index [2] - Following the Q3 2025 report, FMC lost nearly half of its market capitalization and recorded its worst single-day performance [2] Industry Challenges - FMC faces macroeconomic challenges within the agricultural chemicals industry, particularly a demand-supply mismatch, with tepid demand and expanding capacity, especially in the generic segment [4] - The company is exiting the Indian market and has marked down the fair value of that business to $450 million [4] Supply Chain Issues - Tariffs on China are exacerbating FMC's situation, as the company incurs upfront costs that take a long time to recover due to the lengthy supply chain and high inventory issues [5] Competitive Landscape - FMC's core portfolio, consisting of post-patent or nearing-patent products, is facing intense competition, with specific mention of Rynaxypyr, which is experiencing non-competitive manufacturing costs and delayed customer purchases ahead of generics entering the market in early 2026 [6] Growth Prospects - While FMC's growth portfolio, featuring newly launched patent-protected products, has provided some offset to the slowdown, the growth is still limited, with expectations for significant contributions only by 2028 and a challenging year anticipated in 2026 [7]
This Dividend Stock Got Butchered After Q3 Earnings: Time to Buy the Dip?